Flag of the European Union EU Clinical Trials Register Help

Clinical trials for CXCL13

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    8 result(s) found for: CXCL13. Displaying page 1 of 1.
    EudraCT Number: 2018-004947-21 Sponsor Protocol Number: CLAD19 Start Date*: 2019-06-26
    Sponsor Name:Azienda Ospedaliera Universitaria Integrata Verona
    Full Title: Exploring the intrathecal anti-inflammatory effect of cladribine and its relationship with clinical efficacy
    Medical condition: highly active relapsing multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10063399 Relapsing-remitting multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-004414-10 Sponsor Protocol Number: TERIFL08519 Start Date*: 2018-02-23
    Sponsor Name:MS Centrum, Department of Neurology, Sshlgrenska University Hospital
    Full Title: Determination of the concentration of Teriflunomide in serum and cerebrospinal fluid from patients with multiple sclerosis who are treated with Teriflunomide 14 mg daily.
    Medical condition: Multiple Sclerosis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2023-000142-42 Sponsor Protocol Number: GR-2021-12373041 Start Date*: 2023-04-17
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA
    Full Title: Exploring the effect of a novel therapy on chronic intrathecal inflammation in patients with active progressive multiple sclerosis
    Medical condition: patients with secondary progressive MS
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10053395 Progressive multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-016703-35 Sponsor Protocol Number: NAPMSv3.2 Start Date*: 2010-01-08
    Sponsor Name:Dansk Multipel Sclerose Center
    Full Title: Natalizumabbehandling af progressiv multipel sklerose
    Medical condition: Secondary progressive multiple sclerosis and primary progressive multiple sclerosis
    Disease: Version SOC Term Classification Code Term Level
    12.0 10063400 Secondary progressive multiple sclerosis LLT
    12.0 10063401 Primary progressive multiple sclerosis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2023-000018-16 Sponsor Protocol Number: OZA22/IM047-048 Start Date*: 2023-04-19
    Sponsor Name:AZIENDA OSPEDALIERA UNIVERSITARIA INTEGRATA VERONA
    Full Title: Effect of ozanimod on meningeal inflammation and glial activation in Multiple Sclerosis: one year phase 4 experimental study
    Medical condition: Relapsing Multiple Sclerosis (relapsing-remitting, relapsing-progressive)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029205 - Nervous system disorders 10080700 Relapsing multiple sclerosis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003909-17 Sponsor Protocol Number: OA-CL-LYM-LYSARC-13134 Start Date*: 2018-11-12
    Sponsor Name:LYSARC
    Full Title: Randomized Phase 3 Study evaluating the Efficacy and the Safety of Oral Azacitidine (CC-486) compared to Investigator’s Choice Therapy in Patient with Relapsed or Refractory Angioimmunoblastic T ce...
    Medical condition: Angioimmunoblastic T cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002452 Angioimmunoblastic T-cell lymphoma recurrent PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10002453 Angioimmunoblastic T-cell lymphoma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) AT (Completed) GB (GB - no longer in EU/EEA) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001480-23 Sponsor Protocol Number: IMMUNIB Start Date*: 2019-02-22
    Sponsor Name:Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
    Full Title: IMMUNIB - An open-label, single-arm phase II study of immunotherapy with nivolumab in combination with lenvatinib for advanced stage hepatocellular carcinoma (HCC)
    Medical condition: advanced stage hepatocellular carcinoma (HCC)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10019828 Hepatocellular carcinoma non-resectable LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10073071 Hepatocellular carcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10077738 Hepatocellular carcinoma metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005843-40 Sponsor Protocol Number: PXD101-CLN-19 Start Date*: 2008-11-11
    Sponsor Name:Spectrum Pharmaceuticals Inc.
    Full Title: A Multicenter, Open-Label Trial of Belinostat in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma
    Medical condition: Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004851 10034622 Peripheral T-cell lymphomas NEC HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) FR (Completed) IT (Completed) NL (Completed) BE (Completed) DE (Completed) ES (Completed) HU (Completed) SK (Completed) PL (Completed) GB (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 07:51:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA